Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease

[1]  A. Santoro,et al.  Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study , 2017, Journal of Nephrology.

[2]  J. Segal,et al.  Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis , 2016, BMC Nephrology.

[3]  D. Brancaccio,et al.  Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study , 2016, American Journal of Nephrology.

[4]  J. Saver,et al.  Warfarin Use and Risk of Stroke in Patients With Atrial Fibrillation Undergoing Hemodialysis , 2016, Medicine.

[5]  D. Tarng,et al.  Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort , 2016, Circulation.

[6]  A. Gross,et al.  Frailty and Cognitive Function in Incident Hemodialysis Patients. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[7]  Ming Long,et al.  Effectiveness and Safety of Warfarin in Dialysis Patients With Atrial Fibrillation , 2015, Medicine.

[8]  Jenny I. Shen,et al.  Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Gaosi Xu,et al.  Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: A systematic review and a meta-analysis. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[10]  D. Segev,et al.  Perceived frailty and measured frailty among adults undergoing hemodialysis: a cross-sectional analysis , 2015, BMC Geriatrics.

[11]  N. Abraham,et al.  Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study , 2015, BMJ : British Medical Journal.

[12]  M. Lamberts,et al.  Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.

[13]  J. Healey,et al.  2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. , 2014, The Canadian journal of cardiology.

[14]  David M. Smith,et al.  Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation , 2014, Current medical research and opinion.

[15]  J. Tu,et al.  Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis , 2014, Circulation.

[16]  J. Carrero,et al.  Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. , 2014, JAMA.

[17]  A. Santoro,et al.  The nephrologist’s anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation , 2014, Journal of Nephrology.

[18]  D. Segev,et al.  Frailty and falls among adult patients undergoing chronic hemodialysis: a prospective cohort study , 2013, BMC Nephrology.

[19]  L. Moist,et al.  Warfarin use in hemodialysis patients with atrial fibrillation: decisions based on uncertainty , 2013, BMC Nephrology.

[20]  D. Segev,et al.  Frailty as a Novel Predictor of Mortality and Hospitalization in Individuals of All Ages Undergoing Hemodialysis , 2013, Journal of the American Geriatrics Society.

[21]  J. Gagne,et al.  Estimation using all available covariate information versus a fixed look‐back window for dichotomous covariates , 2013, Pharmacoepidemiology and drug safety.

[22]  J. Goodwin,et al.  National Utilization Patterns of Warfarin Use in Older Patients with Atrial Fibrillation: A Population-Based Study of Medicare Part D Beneficiaries , 2013, The Annals of pharmacotherapy.

[23]  Jenny I. Shen,et al.  Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks? , 2012, Current opinion in nephrology and hypertension.

[24]  C. Clase,et al.  Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[26]  James Floyd,et al.  A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.

[27]  W. Winkelmayer,et al.  Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[28]  W. Ray,et al.  An automated database case definition for serious bleeding related to oral anticoagulant use , 2011, Pharmacoepidemiology and drug safety.

[29]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[30]  W. Winkelmayer,et al.  The increasing prevalence of atrial fibrillation among hemodialysis patients. , 2011, Journal of the American Society of Nephrology : JASN.

[31]  Felix Yang,et al.  Warfarin in haemodialysis patients with atrial fibrillation: what benefit? , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[32]  H. Büller,et al.  Safety and efficacy of anticoagulation for secondary stroke prevention in atrial fibrillation patients: The AMADEUS trial , 2010 .

[33]  V. Budhraja.  The net clinical benefit of warfarin anticoagulation in atrial fibrillation. , 2010, Annals of internal medicine.

[34]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[35]  P. Komenda,et al.  The intersection of risk and benefit: is warfarin anticoagulation suitable for atrial fibrillation in patients on hemodialysis? , 2009, Chest.

[36]  W. Bennett.  Should dialysis patients ever receive warfarin and for what reasons? , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[37]  A. Laupacis,et al.  Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. , 2006, The American journal of medicine.

[38]  Michael D. Hill,et al.  Coding of Stroke and Stroke Risk Factors Using International Classification of Diseases, Revisions 9 and 10 , 2005, Stroke.

[39]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[40]  Robby Nieuwlaat,et al.  Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey , 2012 .

[41]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .